|
 The study involved 499 medical workers - 100 receiving mixed doses,
200 taking two doses of the Pfizer/BioNTech shot and the remainder
getting two AstraZeneca shots.
All showed neutralizing antibodies, which prevent the virus from
entering cells and replicating, and the result of the mixed schedule
of vaccines showed similar amounts of neutralizing antibodies found
from the group that received two Pfizer shots.
A British study last month showed similar results - an AstraZeneca
shot followed by Pfizer produced the best T-cell responses, and a
higher antibody response than Pfizer followed by AstraZeneca.
The data provides further support for the decision of several
countries to offer alternatives to AstraZeneca as a second shot
after the vaccine was linked to rare blood clots.
[to top of second column] |
The South Korean study also analysed neutralizing activity against
major variants of concern, the Korea Disease Control and Prevention
Agency (KDCA) said.
None of the groups demonstrated reduced neutralising activity
against the Alpha variant, first identified in Britain, but the
neutralization titre decreased by 2.5 to 6 fold against Beta, Gamma
and Delta, first detected in South Africa, Brazil and India
respectively.
(Reporting by Sangmi Cha; Editing by Miyoung Kim and Nick Macfie)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
